Results 181 to 190 of about 6,312 (217)
Some of the next articles are maybe not open access.

Combining chemotherapy and immune checkpoint blockade

Current Opinion in Urology, 2016
Immune checkpoint blockade results in durable responses in a subset of patients with advanced urologic tumors. However, the majority of patients do not respond to single agent therapy raising the hypothesis that combination regimens may extend the benefits of immune checkpoint blockade to an even broader patient population.
Ana, Collazo-Lorduy, Matthew D, Galsky
openaire   +2 more sources

A Review of Immune Checkpoint Blockade for the General Surgeon

Journal of Surgical Research, 2023
The immune system is a complex and interconnected system that has evolved to protect its host from foreign pathogens. CD8+ T cells are a type of immune cell that can be directly lethal to tumor cells. However, their tumor killing capabilities can be inhibited by checkpoint molecules.
Xavier L. Baldwin   +2 more
openaire   +2 more sources

Delivery Strategies for Immune Checkpoint Blockade

Advanced Healthcare Materials, 2018
AbstractImmune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers.
Qian Chen   +4 more
openaire   +2 more sources

Combination of Photodynamic Therapy and Immune Checkpoint Blockade

2022
Photodynamic therapy (PDT) for cancer not only strongly reduces tumor mass but can also induce or enhance immune responses against the tumor by causing the release of tumor antigen and danger signals from dying tumor cells. This supports combinations of PDT and immunotherapy for the treatment of advanced tumors for which single therapies are ...
Jan Willem, Kleinovink, Ferry, Ossendorp
openaire   +2 more sources

Double immune checkpoint blockade in advanced NSCLC

Critical Reviews in Oncology/Hematology, 2020
Immunotherapy-based options for patients with advanced non-small cell lung cancer (NSCLC) are increasing at an unprecedented pace, carrying the promise to prolong survival of this deadly disease. To maximize responses and extend benefit to a larger portion of patients, immunotherapy combination strategies are currently under investigation, with chemo ...
Mariniello A.   +3 more
openaire   +3 more sources

Presurgical immune checkpoint blockade

Science, 2020
Cancer Immunotherapy Checkpoint blockade immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al.
openaire   +1 more source

Microbiome dynamics in immune checkpoint blockade

Trends in Endocrinology & Metabolism
Immune checkpoint blockade (ICB) is one of the leading immunotherapies, although a variable extent of resistance has been observed among patients and across cancer types. Among the efforts underway to overcome this challenge, the microbiome has emerged as a factor affecting the responsiveness and efficacy of ICB.
Chae Won Kim   +2 more
openaire   +2 more sources

Immune checkpoint blockades therapy of melanoma

Science Bulletin, 2023
Hong, Liu   +3 more
openaire   +2 more sources

Immune Checkpoint Blockade

2021
Annamaria Brioli, Andreas Hochhaus
openaire   +1 more source

Immune Checkpoint Blockade in Metastatic Urothelial Cancer

Journal of Clinical Oncology, 2017
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches.
openaire   +2 more sources

Home - About - Disclaimer - Privacy